SUPN News and Press, Supernus Pharmaceuticals Inc.

2026-05-30 23:31:08 ET ... Read the full article on Seeking Alpha For further details see: Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the follow...

2026-05-13 01:10:44 ET Supernus Pharmaceuticals, Inc. (SUPN) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDT... Read the full article on Seeking Alpha For further details see: Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global...

2026-05-12 13:10:43 ET On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it sold out its entire stake in Supernus Pharmaceuticals (NASDAQ:SUPN) during the first quarter, with an estimated transaction value of $4.56 million based on quarterly average pricing. Acc...

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Sup...

2026-05-05 22:22:08 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Supernus Pharmaceuticals, Inc...

2026-05-05 22:21:16 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

2026-05-05 18:44:32 ET Image source: The Motley Fool. May 5, 2026 Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-05 16:49:33 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript Supernus Pharmaceuticals Q1 2...

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. T...